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We read with interest the recent 
report by Garner et al. [l], in which 
anti-E was detected early in pregnan- 
cy solely through the use of enzyme- 
treated red blood cells (RBC). The 
serological reactivity of this anti-E 
changed dramatically during preg- 
nancy; the antibody became detecta- 
ble by the indirect antiglobulin test, 
and at 37 weeks’ gestation had a titer 
of 512. Delivery at 40 weeks’ gesta- 
tion yielded an infant affected with 
hemolytic disease of the newborn 
(HDN) requiring exchange transfu- 
sion and 4 days of phototherapy. This 
case was further complicated by anti- 
K1, stimulated by prior transfusions, 
that was present throughout the preg- 
nancy but did not contribute to  the 
HDN, and an anti-c that was detected 
solely in tests with enzyme-treated 
RBCs at 35 weeks’ gestation, but was 
not demonstrable in the infant at de- 
livery. 
While we concur with the authors 
that there is a need to screen both Rh 
D-positive and Rh D-negative wom- 
en for RBC alloantibodies early in 
pregnancy, and while we agree that 
once an antibody has been detected it 
should be identified and evaluated 
for its potential to cause HDN, we 
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cannot condone the routine use of en- 
zyme-treated RBCs when screening 
for unexpected antibodies for the fol- 
lowing reasons. First, we are unaware 
of documented cases in which an an- 
ti-D was detected for the first time at 
28 weeks’ gestation solely by tests 
with enzyme-treated RBC, yet there 
was severe HDN that warranted 
medical intervention (e.g. intraute- 
rine transfusion, induction) before 
full-term delivery. Second, we are un- 
aware of documented cases in which 
an antibody other than anti-D was de- 
tected solely by tests with enzyme- 
treated RBC during the first trimes- 
ter, yet there was severe HDN that 
warranted medical intervention be- 
fore full-term delivery. Since medical 
intervention was not reported to have 
taken place in the case described by 
Garner et al. [l], we remain so un- 
aware. Third, Issitt [2] recently con- 
firmed what most USA investigators 
have long claimed: the incidence of 
unwanted positive tests is such that 
use of enzyme-treated RBC for anti- 
body detection is not warranted in an 
era of limited resources. Moreover, 
further support for our position is to 
be found in the 1990 guidelines prom- 
ulgated by a committee of the Scien- 
tific Section of the American Associ- 
ation of Blood Banks [3]. 
These guidelines recommend test- 
ing prenatal patients for unexpected 
antibodies during the first trimester 
by methods that detect antibodies 
known to cause HDN. Routine test- 
ing for unexpected antibodies later in 
pregnancy is recommended for Rh D- 
negative women, at 28-30 weeks’ ges- 
tation, to document the absence of 
alloimmunization to D and verify the 
need for prophylactic Rh immune 
globulin therapy. Because of the 
paucity of alloantibodies other than 
D that necessitate medical interven- 
tion before full-term delivery [4], the 
cost-effectiveness of routinely testing 
Rh D-positive prenatal patients again 
for unexpected alloantibodies during 
the third trimester must be ques- 
tioned. However, such testing is rec- 
ommended for all pregnant women, 
regardless of Rh type, when there is a 
history of previous transfusions or 
traumatic deliveries. Also, periodic 
testing for additional antibodies dur- 
ing the third trimester is recommend- 
ed for women with preexisting alloan- 
tibodies or a history thereof [2,5]. 
Under these latter protocols, the 
patient described by Garner et al. [l] 
0 1992 S Kerger AG. Basel 
O(W2-~(XI7/92/0h34-02’)3 
$2.75/0 
would have been retested during the 
third trimester, since there was both a 
history of transfusion and a preexist- 
ing anti-K1. One can assume that the 
anti-E would have been detected by 
indirect antiglobulin test with un- 
treated RBCs, but even if these fol- 
low-up studies were not performed or 
were nonreactive, the outcome and 
clinical management of the pregnan- 
cy would have been no different than 
that reported. In spite of the high an- 
ti-E titers and antibody-dependent 
cell cytotoxicity (ADCC) assay val- 
ues, there was no reported medical 
intervention during the latter stages 
of the pregnancy, nor did the authors 
report that they monitored for HDN 
by nonserological means, such as am- 
niotic fluid analysis, ultrasonography 
or percutaneous umbilical blood sam- 
pling. 
Thus, we must also question the 
value of performing titration studies 
after the antibody titer exceeds the 
critical value of 16. For Rh antibodies, 
this is the level above which, in the 
USA, fetal monitoring by nonsero- 
logical means is considered indicated 
[2,5,6]. Rather than performing 
time-consuming and unnecessary ti- 
tration studies, it would seem more 
appropriate to manage cases similar 
to the one under discussion by mon- 
itoring the anti-E until it exceeds the 
critical titer, after which no further ti- 
trations are performed. Instead, sub- 
sequent assessment for the potential 
for HDN should include amniotic 
fluid analysis, ultrasonography or 
percutaneous umbilical blood sam- 
pling, as indicated. Under such a re- 
gimen, the need for fetal transfusions 
or early delivery can be addressed in 
order to minimize the potential physi- 
ological, hematological and neuro- 
logical adverse effects associated with 
untreated HDN. 
Clearly there are fundamental dif- 
ferences between the UK and USA 
health-care delivery systems. What is 
deemed appropriate in one setting 
may be impractical in another. How- 
ever, efforts to curtail escalating costs 
are of paramount concern to health- 
care workers in both countries. On 
this side of the Atlantic, we would 
question not only the recommended 
tests with enzyme-treated RBC and 
the needless anti-E titrations, but al- 
so the titration of anti-K1 when the 
father is K:-1, the value of the ADCC 
assay when alleged significant data do 
not prompt medical intervention of 
pregnancy, and the performance of 
cord blood elution studies when ma- 
ternal alloantibodies are clearly iden- 
tified. 
It could be argued that the anti-K1 
might contribute to HDN if the hus- 
band was not the father, but if pater- 
nity is in question there seems little 
value in phenotyping the husband’s 
RBC to begin with! Doubtless the 
ADCC data are interesting and infor- 
mative, but what is their utility? Simi- 
larly, the elution data are of interest, 
and document the noninvolvement of 
anti-K1 in contributing to the hemo- 
lytic disease; however, regardless of 
the specificity of antibodies reco- 
vered by elution, appropriate trans- 
fusion management of the infant ne- 
cessitates the selection of E- and K:-1 
blood. 
In the current economic environ- 
ment it is prudent, if not essential, to 
eliminate tests unless the data ob- 
tained will aid in diagnosis or be used 
to modify patient care [7]. In the case 
under review [ 3 ] ,  many of the data 
generated fail to satisfy either crite- 
ria. 
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